A Six-week, Randomized, Double-blind, Parallel-group, Multicenter Study to Evaluate the Safety and Efficacy of the Combination of Aliskiren 150 mg and Amlodipine 5 mg Compared to Amlodipine 5 mg and 10 mg in Hypertensive Patients Not Adequately Responsive to Amlodipine 5 mg
Phase of Trial: Phase III
Latest Information Update: 24 May 2017
At a glance
- Drugs Aliskiren (Primary) ; Amlodipine
- Indications Essential hypertension; Hypertension
- Focus Registrational; Therapeutic Use
- Sponsors Novartis
- 28 Sep 2008 Actual start date (Feb 2005) added as reported by ClinicalTrials.gov.
- 28 Sep 2008 Actual end date (Oct 2005) added as reported by ClinicalTrials.gov.
- 29 Oct 2005 New trial record.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History